Poor, S. H., Weissgerber, G., Adams, C. M., Bhatt, H., Browning, D. J., Chastain, J., . . . Grosskreutz, C. L. (2022). A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. American journal of ophthalmology, 239, 180-189. https://doi.org/10.1016/j.ajo.2022.02.019
Chicago-Zitierstil (17. Ausg.)Poor, Stephen H., et al. "A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration." American Journal of Ophthalmology 239 (2022): 180-189. https://doi.org/10.1016/j.ajo.2022.02.019.
MLA-Zitierstil (9. Ausg.)Poor, Stephen H., et al. "A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration." American Journal of Ophthalmology, vol. 239, 2022, pp. 180-189, https://doi.org/10.1016/j.ajo.2022.02.019.